The funds will be used to meet the working capital requirements of DRL Russia, which operates as a pharmaceutical distribution company in the Russian Federation. DRL Russia reported a turnover of ₹2,347 crore for FY2025. Shares of Dr Reddy’s Laboratories Ltd ended at ₹1,277.10, up by ₹12.25, or 0.97%, on the BSE.
